康普頓(603798.SH)控股股東提前終止減持計劃 累計減持440萬股
格隆匯4月3日丨康普頓(603798.SH)公佈,公司控股股東路邦化工於2020年1月8日至2020年2月6日合計減持公司股份440萬股,佔公司股份總數的2.20%。鑑於減持計劃的數量已過半,基於自身的資金需求情況,路邦化工決定提前終止本次股份減持計劃。
截至本公告披露日,路邦化工持有公司股份5497萬股,佔公司總股本的27.485%,恆嘉世科國際(香港)有限公司(以下簡稱“恆嘉世科”)持有公司股份5523萬股,佔公司總股本的27.615%。上述股東構成一致行動關係,合計持有公司股份1.102億股,佔公司總股本的55.10%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.